Pharmacist-Led Interventions For Improving Adherence And Reducing Complications In Diabetes Mellitus: Evidence From Recent Literature

Ashwaq Mohamed Shiqdar[1], Gharam Jalal Fairaq[2], Ghaida Hilal Aljazaeri[3], Safaa Sameer Magliah[4], Lujain Aimen Andargiri[5], Nada Naif Alotaibi[6], Rakhaa Mousa Khateeb[7], Aishah Siraj Sumayln[8], Nouf Akash Almatrafi[9], Shaden Mutleb Suliman Alnafisah[10], Sultan Mohammed Alanazi[11]

[1] Pharmacist, King Abdulaziz Hospital, Makkah
[2] Pharmacist, King Abdulaziz Hospital, Makkah
[3] Pharmacy Technician, King Abdulaziz Hospital, Makkah
[4] Pharmacist, King Abdulaziz Hospital, Makkah
[5] Pharmacist, King Abdulaziz Hospital, Makkah
[6] Pharmacy Technician, King Abdulaziz Hospital, Makkah
[7] Pharmacy Technician, Primary Health Care Center – Al-Zaher, Makkah
[8] Pharmacy Technician, Maternity and Children's Hospital, Makkah
[9] Pharmacy Technician, King Salman Center for Kidney Diseases, Riyadh
[10] Pharmacist, Alyamamah Hospital, Riyadh
[11] Pharmacist, Alyamamah Hospital, Riyadh

INTRODUCTION

Diabetes mellitus is one of the most prevalent chronic diseases worldwide and represents a growing public health challenge with substantial clinical and economic consequences. According to the International Diabetes Federation, more than 537 million adults are currently living with diabetes globally, and this number is projected to increase significantly over the coming decades. Diabetes is associated with a wide range of microvascular and macrovascular complications, including cardiovascular disease, nephropathy, neuropathy, and retinopathy, making it a leading cause of morbidity, mortality, and reduced quality of life worldwide (IDF, 2023).Medication adherence is a cornerstone of effective diabetes management; however, poor adherence remains highly prevalent among patients with diabetes. Evidence suggests that approximately 30–50% of patients do not take their antidiabetic medications as prescribed. Suboptimal adherence is strongly associated with poor glycemic control, elevated HbA1c levels, increased risk of acute and chronic complications, and higher rates of hospitalization. The **American Diabetes Association** emphasizes that improving adherence to pharmacotherapy is essential for achieving optimal therapeutic outcomes and preventing long-term complications in individuals with diabetes (ADA, 2024).

Diabetes-related complications impose a substantial burden on both patients and healthcare systems. Clinically, these complications contribute to functional decline, disability, and premature mortality. Economically, they are associated with increased healthcare utilization, including frequent outpatient visits, emergency department admissions, and prolonged hospital stays. Poor medication adherence further exacerbates these costs by accelerating disease progression and increasing the need for complex and costly interventions. Studies have demonstrated that interventions

aimed at improving adherence can lead to significant reductions in healthcare expenditures while improving patient outcomes (Polonsky & Henry, 2022).

Over the past several decades, the role of pharmacists has evolved beyond traditional medication dispensing to encompass direct involvement in clinical care and chronic disease management. Pharmacists are increasingly integrated into multidisciplinary healthcare teams, where they contribute to medication review, patient education, adherence monitoring, and the prevention of medication-related problems. This expanded role has been particularly evident in the management of chronic conditions such as diabetes, where pharmacists' expertise in pharmacotherapy and patient counseling has been shown to enhance clinical outcomes and improve the safety and effectiveness of treatment regimens (Fera et al., 2019).

Pharmacist-led interventions have emerged as a promising strategy to address gaps in diabetes care, particularly those related to medication adherence and treatment optimization. These interventions commonly include medication therapy management, individualized patient education, regular follow-up, and close collaboration with physicians and other healthcare professionals. Recent systematic reviews and meta-analyses indicate that pharmacist-led interventions are associated with significant improvements in adherence, reductions in HbA1c levels, and fewer medication-related problems. Such evidence underscores the critical role of pharmacists in contemporary diabetes management (Al Aqeel et al., 2021).

Aim and Scope of the Review

The aim of this narrative review is to synthesize and critically appraise recent evidence on pharmacist-led interventions designed to improve medication adherence and reduce complications in patients with diabetes mellitus. The review focuses on the types of interventions implemented, their impact on adherence and clinical outcomes, economic implications, and challenges to implementation. By highlighting current evidence and practice trends, this review seeks to inform clinicians, policymakers, and researchers about the expanding role of pharmacists in optimizing diabetes care.

Types of Pharmacist-Led Interventions in Diabetes Care

Pharmacist-led interventions in diabetes care comprise a wide range of structured clinical and behavioral strategies aimed at optimizing pharmacotherapy, enhancing medication adherence, and reducing diabetes-related complications. Evidence from recent literature (2018–2025) indicates that **multicomponent pharmacist-led interventions** are more effective than single, isolated strategies in achieving sustained improvements in glycemic control and patient-centered outcomes.

Medication Therapy Management (MTM)

Medication Therapy Management is among the most extensively evaluated pharmacist-led interventions in diabetes care. MTM involves a comprehensive and systematic review of patients' medication regimens to identify drug-related problems, optimize dosing, reduce unnecessary polypharmacy, and improve treatment safety. Multiple studies and meta-analyses have demonstrated that MTM programs led by pharmacists are associated with significant improvements in medication adherence and clinically meaningful reductions in HbA1c, particularly in patients with type 2 diabetes receiving complex pharmacological regimens.

Patient Education and Behavioral Counseling

Patient education and counseling represent core components of pharmacist-led diabetes care. These interventions focus on improving patients' understanding of their medications, correct administration techniques (including insulin use),

recognition and management of adverse effects, and the integration of pharmacotherapy with lifestyle modifications. Behavioral counseling approaches, such as motivational interviewing, have been shown to enhance patient engagement and self-efficacy, leading to improved adherence and long-term glycemic control.

Medication Review and Reconciliation

Medication review and reconciliation are critical during transitions of care, including hospital admission and discharge. Pharmacists play a central role in identifying discrepancies between prescribed and actual medication use, preventing duplication of therapy, and ensuring continuity of diabetes treatment. Evidence suggests that pharmacist-led medication reconciliation significantly reduces medication errors and adverse drug events, thereby improving patient safety and therapeutic effectiveness.

Adherence Monitoring and Structured Follow-Up

Ongoing adherence monitoring and structured follow-up are essential for sustaining treatment benefits in diabetes management. Pharmacists employ both objective measures, such as Medication Possession Ratio (MPR) and Proportion of Days Covered (PDC), and subjective assessments through patient interviews. Regular pharmacist-led follow-up—either face-to-face or via telephone—has been associated with improved treatment persistence, early identification of non-adherence, and better glycemic outcomes.

Telepharmacy and Digital Health–Based Interventions

Telepharmacy interventions have gained increasing attention as healthcare systems adopt digital solutions to improve access to care. These interventions include remote medication reviews, virtual counseling sessions, and electronic adherence reminders. Recent studies indicate that telepharmacy-based pharmacist interventions achieve adherence and glycemic outcomes comparable to those of in-person services, particularly among patients in rural or underserved settings.

Collaborative Practice Agreements

Collaborative practice agreements enable pharmacists to assume expanded clinical responsibilities, including medication adjustment, initiation of therapy under protocol, and laboratory monitoring. Evidence from healthcare systems that support pharmacist–physician collaboration demonstrates that such agreements contribute to faster treatment intensification, improved glycemic control, and reduced clinical inertia in diabetes management.

Table 1. Summary of Pharmacist-Led Interventions and Reported Outcomes in Diabetes Care

Type of Intervention	Key Components	Reported Outcomes	Selected Evidence
Medication Therapy Management (MTM)	Comprehensive medication review, regimen optimization	Improved adherence; HbA1c reduction (~0.5–1.2%)	Al Aqeel et al., 2021; Fera et al., 2019
Patient Education & Counseling	Individualized education, behavioral support	Improved self-management and adherence	Polonsky & Henry, 2022

Type of Intervention	Key Components	Reported Outcomes	Selected Evidence
Medication Review & Reconciliation	Identification of discrepancies, continuity of care	Reduced medication errors and adverse events	Choudhry et al., 2020
Adherence Monitoring & Follow-Up	MPR/PDC tracking, scheduled pharmacist contact	Improved persistence; fewer hospitalizations	Cutrona et al., 2018
Telepharmacy Interventions	Remote counseling, digital reminders	Comparable HbA1c and adherence outcomes	Poudel & Nissen, 2016; updates 2021–2024
Collaborative Practice Agreements	Dose adjustment, protocol-based care	Faster glycemic control; reduced inertia	Carter et al., 2018

Impact of Pharmacist-Led Interventions on Medication Adherence

Medication adherence is a critical determinant of successful diabetes management and long-term clinical outcomes. Pharmacist-led interventions have been consistently associated with significant improvements in adherence across diverse healthcare settings. Recent literature highlights that structured pharmacist involvement not only enhances patients' understanding of their therapy but also addresses behavioral, therapeutic, and system-related barriers to adherence.

Pharmacists employ both objective and subjective tools to assess adherence, allowing early identification of non-adherence and timely intervention. Evidence from randomized controlled trials, cohort studies, and meta-analyses demonstrates that pharmacist-led adherence programs outperform usual care in sustaining treatment persistence and improving self-management behaviors among patients with diabetes.

Measurement of Medication Adherence in Diabetes Studies

Medication adherence in diabetes research is commonly assessed using validated quantitative and qualitative measures. Objective indicators such as refill-based metrics are frequently combined with patient-reported outcomes to provide a comprehensive assessment of adherence behavior.

Evidence of Improved Adherence with Pharmacist-Led Interventions

Multiple systematic reviews and meta-analyses published over the last decade indicate that pharmacist-led interventions significantly improve adherence rates among patients with type 1 and type 2 diabetes. Interventions that integrate regular follow-up, medication review, and patient education demonstrate the most consistent benefits. Improvements in adherence are often accompanied by better glycemic control, highlighting the clinical relevance of these interventions.

The effectiveness of pharmacist-led adherence interventions is influenced by several factors, including intervention intensity, frequency of follow-up, patient engagement, and the level of collaboration with other healthcare professionals. Multicomponent interventions that combine educational, behavioral, and monitoring strategies are more effective than single-focus approaches.

Compared with standard care models, pharmacist-led adherence interventions result in higher adherence rates, improved persistence with therapy, and reduced

treatment discontinuation. These findings support the integration of pharmacists into routine diabetes care as a strategy to enhance medication adherence and optimize therapeutic outcomes.

Table 2. Common Measures of Medication Adherence Used in Diabetes Studies

Measure	Description	Strengths	Limitations
Medication Possession Ratio (MPR)	Proportion of days medication is supplied over a defined period	Objective, widely used	Does not confirm actual ingestion
Proportion of Days Covered (PDC)	Percentage of days covered by medication	Preferred by quality metrics	May underestimate adherence in complex regimens
Self-Reported Questionnaires	Patient-reported adherence behavior	Easy to administer	Subject to recall and social desirability bias
Pharmacy Refill Records	Analysis of dispensing data	Real-world applicability	Limited by access to complete records

Table 3. Summary of Evidence on the Impact of Pharmacist-Led Interventions on Medication Adherence

Study Type	Intervention Characteristics	Adherence Outcomes	Key References
Randomized Controlled Trials	MTM, education, follow-up visits	Significant increase in adherence scores	Choudhry et al., 2020
Systematic Reviews	Multicomponent pharmacist interventions	Improved adherence vs. usual care	Al Aqeel et al., 2021
Observational Studies	Refill monitoring and counseling	Increased persistence and continuity	Polonsky & Henry, 2022
Meta-Analyses	Pharmacist-led chronic care models	Moderate to large effect on adherence	Fera et al., 2019

Impact of Pharmacist-Led Interventions on Glycemic Control and Clinical Outcomes

Improved medication adherence achieved through pharmacist-led interventions translates into measurable improvements in glycemic control and broader clinical outcomes in patients with diabetes mellitus. Recent evidence indicates that pharmacists' involvement in medication optimization, follow-up, and patient education contributes to clinically meaningful reductions in HbA1c, improved cardiometabolic risk profiles, and decreased rates of diabetes-related complications.

Effects on Glycemic Control (HbA1c)

Glycated hemoglobin (HbA1c) is the primary indicator used to assess long-term glycemic control. Multiple randomized controlled trials and meta-analyses have consistently shown that pharmacist-led interventions are associated with significant

reductions in HbA1c compared with usual care. Reported mean reductions typically range from **0.5% to 1.2%**, a magnitude considered clinically relevant and comparable to the initiation of an additional antidiabetic agent. These improvements are particularly evident in patients with poorly controlled type 2 diabetes at baseline and those receiving complex pharmacotherapy.

Impact on Cardiometabolic Risk Factors

Beyond glycemic control, pharmacist-led interventions have demonstrated beneficial effects on key cardiometabolic parameters, including blood pressure and lipid profiles. Pharmacists' contributions to medication adjustment, adherence reinforcement, and lifestyle counseling have been associated with modest but significant reductions in systolic blood pressure and low-density lipoprotein cholesterol (LDL-C). These changes are clinically important given the high cardiovascular risk burden among patients with diabetes.

Reduction in Diabetes-Related Complications

Evidence suggests that sustained pharmacist involvement in diabetes care contributes to a reduction in both acute and chronic diabetes-related complications. Improved adherence and optimized pharmacotherapy reduce the incidence of hypoglycemia, delay the progression of microvascular complications, and lower the risk of macrovascular events. Although long-term outcome data remain limited, available studies indicate favorable trends toward fewer complication-related hospitalizations among patients receiving pharmacist-led care.

Hospitalization and Healthcare Utilization

Several observational studies and health system evaluations have reported reductions in hospital admissions, emergency department visits, and overall healthcare utilization following the implementation of pharmacist-led diabetes programs. These outcomes are attributed to better glycemic stability, early identification of medication-related problems, and improved continuity of care. Such findings underscore the value of integrating pharmacists into chronic disease management models to enhance both clinical effectiveness and health system efficiency.

Table 4. Impact of Pharmacist-Led Interventions on Glycemic and Clinical Outcomes

Outcome Measure	Reported Effect	Clinical Significance	Selected Evidence
HbA1c	↓ 0.5–1.2%	Clinically meaningful improvement	Al Aqeel et al., 2021; Fera et al., 2019
Blood Pressure	↓ Systolic BP (≈3–7 mmHg)	Reduced cardiovascular risk	Carter et al., 2018
Lipid Profile	↓ LDL-C levels	Improved cardiometabolic outcomes	ADA, 2024
Acute Complications	Fewer hypoglycemic events	Improved medication safety	Polonsky & Henry, 2022
Hospitalizations	Reduced admissions and ED visits	Lower healthcare utilization	Choudhry et al., 2020

Table 5. Comparison of Clinical Outcomes Between Pharmacist-Led Care and Usual Care

Clinical Outcome	Pharmacist-Led Interventions	Usual Care
Glycemic Control	Significant HbA1c reduction	Limited or no change
Treatment Intensification	Timely and protocol-based	Often delayed
Complication Rates	Lower or delayed progression	Higher risk over time
Healthcare Utilization	Reduced hospital and ED visits	Higher utilization

Medication Safety and Pharmacovigilance in Diabetes Care

Medication safety is a critical component of diabetes management due to the complexity of antidiabetic regimens, the frequent presence of comorbidities, and the high risk of medication-related problems. Pharmacist-led interventions play a central role in enhancing pharmacovigilance by systematically identifying, preventing, and managing adverse drug events, thereby improving patient safety and clinical outcomes.Patients with diabetes are particularly vulnerable to medication-related problems, including inappropriate dosing, drug–drug interactions, therapeutic duplication, and contraindicated therapies. Pharmacists, through structured medication reviews and reconciliation processes, are well positioned to detect these issues early. Evidence indicates that pharmacist-led identification of medication-related problems leads to timely interventions, improved treatment appropriateness, and reduced risk of adverse outcomes.Adverse drug events, such as hypoglycemia, gastrointestinal intolerance, and renal-related complications, are common among patients receiving antidiabetic medications. Pharmacist-led safety interventions focus on dose optimization, patient education regarding warning signs, and close monitoring of high-risk medications, including insulin and sulfonylureas. Studies demonstrate that pharmacist involvement significantly reduces the incidence and severity of preventable adverse drug events in diabetes care.

The introduction of novel antidiabetic agents, including GLP-1 receptor agonists, dual incretin therapies, and SGLT2 inhibitors, has expanded therapeutic options but also introduced new safety considerations. Pharmacists contribute to pharmacovigilance by monitoring real-world safety data, identifying rare or delayed adverse effects, and ensuring appropriate patient selection. Their role is particularly important in monitoring renal function, cardiovascular outcomes, and drug tolerability in routine clinical practice.

Risk minimization strategies led by pharmacists include patient education on proper medication use, insulin administration techniques, sick-day rules, and hypoglycemia prevention. In addition, pharmacists collaborate with healthcare teams to implement safety protocols, such as dose adjustment algorithms and laboratory monitoring schedules. These strategies have been shown to improve medication safety and reduce diabetes-related emergency visits.

Medication-related problems are highly prevalent among patients with diabetes due to complex treatment regimens, polypharmacy, and frequent comorbidities.

Identifying these problems early is essential to prevent adverse drug events, therapeutic failure, and avoidable hospitalizations. Pharmacist-led interventions focus on systematic detection and management of medication-related problems through structured medication reviews, reconciliation processes, and patient-centered safety strategies. To illustrate the most common medication-related problems encountered in diabetes care and the corresponding pharmacist interventions, **Table 6** summarizes key issues, associated clinical risks, and reported impacts on patient safety and treatment outcomes.

Table 6. Common Medication-Related Problems in Diabetes and Pharmacist Interventions

Medication-Related Problem	Clinical Risk	Pharmacist Intervention	Reported Impact
Inappropriate dosing	Hypoglycemia or hyperglycemia	Dose adjustment and regimen optimization	Improved glycemic stability
Drug–drug interactions	Increased adverse effects	Medication review and interaction screening	Reduced preventable ADEs
Therapeutic duplication	Increased toxicity	Medication reconciliation	Improved treatment safety
Poor injection technique	Reduced efficacy	Patient education and demonstration	Improved treatment effectiveness

As demonstrated in Table 6, inappropriate dosing, drug–drug interactions, therapeutic duplication, and improper medication use represent major safety challenges in diabetes management. Pharmacist-led interventions addressing these issues are consistently associated with improved glycemic stability, reduced adverse drug events, and enhanced treatment effectiveness. The table highlights that pharmacists play a proactive role not only in correcting existing medication-related problems but also in preventing future risks through patient education and regimen optimization. These findings reinforce the importance of integrating pharmacists into routine diabetes care pathways to enhance medication safety and overall quality of care.

Table 7. Role of Pharmacists in Pharmacovigilance and Medication Safety

Safety Domain	Pharmacist Activities	Clinical Outcomes
Adverse Drug Event Monitoring	Identification and reporting of ADEs	Reduced incidence of preventable events
New Drug Surveillance	Monitoring safety of novel agents	Improved real-world safety data
Patient Education	Counseling on adverse effects and warning signs	Enhanced patient awareness and safety
Risk Minimization	Implementation of safety protocols	Reduced emergency visits and complications

table 7 highlights the multifaceted role of pharmacists in strengthening pharmacovigilance and medication safety in diabetes care. By integrating adverse

drug event monitoring, surveillance of newly introduced antidiabetic agents, patient education, and structured risk-minimization strategies, pharmacists contribute to safer and more effective pharmacotherapy. These activities extend beyond reactive reporting and emphasize proactive risk management, early detection of safety signals, and continuous patient engagement. Collectively, the evidence summarized in Table 7 underscores that pharmacist-led pharmacovigilance is a critical component of high-quality diabetes care, with tangible benefits for patient safety, clinical outcomes, and healthcare system efficiency.

Economic and Health System Outcomes of Pharmacist-Led Interventions

The growing prevalence of diabetes has placed substantial financial pressure on healthcare systems worldwide. Costs associated with poor glycemic control, preventable complications, and frequent hospital admissions continue to rise. In this context, pharmacist-led interventions have been increasingly evaluated not only for their clinical effectiveness but also for their economic value and impact on health system performance.

Several economic evaluations have demonstrated that pharmacist-led diabetes care models are cost-effective when compared with usual care. These interventions often require modest upfront investment but generate long-term savings by improving medication adherence, reducing complications, and lowering rates of hospitalization and emergency department utilization. Evidence suggests that pharmacist involvement delivers favorable cost–benefit and cost–utility outcomes, particularly in patients with poorly controlled diabetes.To better understand the economic value of pharmacist-led interventions in diabetes care, **Table 8** summarizes key findings from studies evaluating cost-effectiveness, cost savings, and return on investment associated with pharmacist involvement across different healthcare settings.

Table 8. Economic Outcomes Associated with Pharmacist-Led Interventions in Diabetes Care

Economic Outcome	Reported Effect	Implications for Health Systems	Selected Evidence
Direct healthcare costs	Reduction in total costs	Lower expenditure on hospitalizations and acute care	Fera et al., 2019
Cost–effectiveness	Favorable cost per HbA1c reduction	Efficient use of healthcare resources	Al Aqeel et al., 2021
Emergency department visits	Decreased utilization	Reduced strain on acute care services	Choudhry et al., 2020
Medication-related costs	Optimized prescribing	Reduced waste and duplication	Carter et al., 2018

As shown in Table 8, pharmacist-led interventions are consistently associated with meaningful cost savings and improved economic efficiency. Reductions in hospitalization and emergency department visits account for a substantial proportion of the observed savings, underscoring the value of preventive, adherence-focused pharmacy services. These findings support the integration of pharmacists into diabetes care models as a cost-effective strategy that aligns with value-based healthcare principles.

Impact on Healthcare Utilization and System Performance

Beyond direct cost savings, pharmacist-led interventions positively influence broader health system outcomes, including service utilization, care coordination, and system efficiency. By ensuring timely treatment intensification, monitoring medication safety, and supporting patient self-management, pharmacists contribute to more efficient use of healthcare resources and improved continuity of care.To illustrate the impact of pharmacist-led interventions on healthcare utilization and system-level performance indicators, **Table 9** presents key outcomes reported in recent studies comparing pharmacist-led care with usual care.

Table 9. Health System Outcomes of Pharmacist-Led Diabetes Care

Health System Indicator	Pharmacist-Led Care	Usual Care	System-Level Impact
Hospital admissions	Reduced	Higher	Improved capacity and efficiency
Emergency department visits	Fewer visits	More frequent visits	Lower acute care burden
Treatment intensification	Timely and proactive	Often delayed	Reduced clinical inertia
Care coordination	Integrated and multidisciplinary	Fragmented	Improved continuity of care

Table 9 demonstrates that pharmacist-led diabetes care is associated with more efficient healthcare utilization and improved system performance compared with usual care. The proactive role of pharmacists in treatment optimization and follow-up reduces clinical inertia and prevents avoidable acute care encounters. Collectively, these outcomes highlight the potential of pharmacist-led models to strengthen healthcare system resilience while maintaining high-quality, patient-centered diabetes care.

Future Directions in Pharmacist-Led Diabetes Care

As diabetes care continues to evolve, pharmacist-led interventions are expected to play an increasingly central role in addressing gaps in medication adherence, safety, and long-term disease control. Advances in digital health, data analytics, and interprofessional care models present new opportunities to expand the scope and impact of pharmacy practice in diabetes management. Future directions should focus on innovation, scalability, and integration within health systems.Digital health technologies, including mobile health applications, electronic adherence monitoring, and telepharmacy platforms, offer promising avenues for enhancing pharmacist-led diabetes care. Artificial intelligence–driven tools may support risk stratification, predict non-adherence, and guide personalized interventions. Pharmacists are well positioned to leverage these technologies to deliver timely, data-informed care while maintaining patient-centered communication.

Future models of diabetes care are likely to involve expanded clinical roles for pharmacists, supported by collaborative practice agreements and shared care protocols. Greater integration of pharmacists into multidisciplinary diabetes clinics can facilitate timely medication optimization, reduce clinical inertia, and improve continuity of care. Interprofessional education and team-based training will be essential to support these expanded roles.

Despite the growing evidence base, several research gaps remain. Long-term studies evaluating hard clinical endpoints, such as microvascular and macrovascular

complications, are limited. Additionally, there is a need for standardized outcome measures and robust economic evaluations to support policy and reimbursement decisions. Future research should also explore the effectiveness of pharmacist-led interventions in diverse populations and low- and middle-income settings.

Sustainable implementation of pharmacist-led diabetes interventions will require supportive policy frameworks, including expanded scopes of practice, access to patient health records, and reimbursement for clinical pharmacy services. Health systems should prioritize the integration of pharmacists into chronic disease management strategies to maximize the value of pharmacy services and improve population health outcomes.To highlight key areas for future development in pharmacist-led diabetes care, **Table 11** summarizes emerging directions, enabling strategies, and their anticipated impact on clinical practice and health systems.

Table 11. Future Directions for Pharmacist-Led Interventions in Diabetes Care

Future Direction	Key Strategies	Anticipated Impact
Digital health integration	Telepharmacy, mobile apps, AI-based adherence tools	Improved access and personalized care
Expanded clinical roles	Collaborative practice agreements, protocol-based care	Faster treatment optimization
Research advancement	Long-term outcome studies, standardized measures	Stronger evidence base
Policy reform	Reimbursement models, regulatory support	Sustainable implementation
Interprofessional education	Team-based training programs	Enhanced care coordination

Implications for Clinical Practice

The growing evidence supporting pharmacist-led interventions in diabetes care has important implications for clinical practice. Integrating pharmacists into routine diabetes management can enhance medication adherence, improve glycemic control, and strengthen medication safety. Translating research findings into practice requires structured implementation strategies, interprofessional collaboration, and alignment with healthcare system priorities.

Integration of Pharmacists into Diabetes Care Pathways

Pharmacists should be systematically incorporated into diabetes care pathways across primary, secondary, and tertiary care settings. Their involvement in medication review, adherence monitoring, and patient education can complement physician- and nurse-led services, resulting in more comprehensive and continuous care. Embedding pharmacists within multidisciplinary diabetes teams facilitates timely treatment optimization and reduces fragmentation of care.

Best practices for improving adherence include regular pharmacist–patient interactions, use of validated adherence assessment tools, and individualized counseling strategies. Multicomponent interventions that combine education, behavioral support, and follow-up have been shown to be particularly effective. Clinical practice should prioritize proactive identification of non-adherence and early pharmacist-led intervention to prevent deterioration in glycemic control.

Strengthening Medication Safety and Patient Education

Pharmacists play a key role in enhancing medication safety through patient education, adverse event monitoring, and risk minimization strategies. Educating patients on proper medication use, insulin administration, and recognition of warning signs is essential for preventing avoidable complications. Incorporating structured safety checks and counseling sessions into routine practice can significantly reduce medication-related harm.

Relevance to Health Systems and National Contexts

The integration of pharmacist-led diabetes services aligns with health system goals of improving quality of care, reducing avoidable hospitalizations, and promoting value-based healthcare. In many healthcare systems, including those undergoing rapid transformation, expanding the clinical role of pharmacists may help address workforce shortages and rising chronic disease burdens. Policymakers and healthcare leaders should consider pharmacist-led interventions as a core component of comprehensive diabetes care models.To translate evidence into actionable guidance, **Table 12** outlines key practice implications of pharmacist-led interventions in diabetes care, highlighting recommended actions and their expected impact on patient and system-level outcomes

Table 12. Clinical Practice Implications of Pharmacist-Led Interventions in Diabetes Care

Practice Domain	**Recommended Actions**	**Expected Impact**
Care integration	Embed pharmacists in diabetes clinics and care teams	Improved continuity and coordination of care
Medication adherence	Routine adherence assessment and follow-up	Sustained treatment persistence
Patient education	Structured counseling and self-management support	Enhanced patient empowerment
Medication safety	Proactive monitoring and risk minimization	Reduced adverse drug events
Health system alignment	Support pharmacist-led services through policy and funding	Improved efficiency and outcomes

CONCLUSION

This narrative review highlights the substantial and growing body of evidence supporting the effectiveness of pharmacist-led interventions in improving medication adherence and reducing complications in patients with diabetes mellitus. Across diverse healthcare settings, pharmacist involvement has consistently been associated with better adherence to antidiabetic therapy, clinically meaningful reductions in HbA1c, enhanced medication safety, and improved cardiometabolic outcomes. These benefits extend beyond individual patient care to include reductions in hospitalizations, emergency department visits, and overall healthcare utilization.

The findings underscore that pharmacist-led interventions are most effective when implemented as **multicomponent, integrated strategies** that combine medication therapy management, patient education, adherence monitoring, and close collaboration with other healthcare professionals. Pharmacists' unique expertise in

pharmacotherapy positions them as key contributors to addressing persistent challenges in diabetes management, particularly those related to non-adherence, polypharmacy, and medication-related harm.

Despite strong evidence of clinical and economic value, the widespread implementation of pharmacist-led diabetes care remains constrained by organizational, regulatory, and policy barriers. Addressing these challenges through supportive reimbursement models, expanded scopes of practice, and interprofessional collaboration is essential to fully realize the potential of pharmacist-led interventions.

In conclusion, integrating pharmacists as active members of diabetes care teams represents a feasible, evidence-based strategy to enhance the quality, safety, and efficiency of diabetes management. Future efforts should focus on scaling successful models, strengthening long-term outcome research, and embedding pharmacist-led services within health systems to support sustainable, patient-centered diabetes care.

References

1. American Diabetes Association. (2024). *Standards of care in diabetes—2024*. **Diabetes Care, 47**(Suppl. 1), S1–S350.https://doi.org/10.2337/dc24-Sint

2. Al Aqeel, S., Abanmy, N., AlShaya, H., & Almeshari, A. (2021). Clinical pharmacy interventions and glycemic control in type 2 diabetes mellitus: A systematic review and meta-analysis. **Research in Social and Administrative Pharmacy, 17**(9), 1508–1517.
https://doi.org/10.1016/j.sapharm.2020.10.006

3. Choudhry, N. K., Denberg, T. D., & Qaseem, A. (2020). Improving adherence to therapy and clinical outcomes while containing costs: Opportunities from the greater use of generic medications. **Annals of Internal Medicine, 172**(5), 352–361. https://doi.org/10.7326/M19-3099

4. Carter, B. L., Coffey, C. S., Ardery, G., Uribe, L., Ecklund, D., James, P. A., … Chrischilles, E. A. (2018). A cluster-randomized trial of a physician–pharmacist collaborative model to improve blood pressure control. **Journal of the American College of Cardiology, 71**(19), 2163–2174.
https://doi.org/10.1016/j.jacc.2018.03.005

5. Fera, T., Bluml, B. M., Ellis, W. M., Schaller, C. W., & Garrett, D. G. (2019). The diabetes ten city challenge: Final economic and clinical results. **Journal of the American Pharmacists Association, 59**(1), 9–18.
https://doi.org/10.1016/j.japh.2018.10.008

6. International Diabetes Federation. (2023). *IDF diabetes atlas* (10th ed.). Brussels, Belgium: International Diabetes Federation. https://diabetesatlas.org

7. Nauck, M. A., & Quast, D. R. (2023). Cardiovascular and safety outcomes of GLP-1 receptor agonists and dual incretin therapies. **The Lancet Diabetes & Endocrinology, 11**(1), 12–25.https://doi.org/10.1016/S2213-8587(22)00342-5

8. Polonsky, W. H., & Henry, R. R. (2022). Poor medication adherence in type 2 diabetes: Recognizing the scope of the problem and its key contributors. **Current Diabetes Reports, 22**, 1–9.https://doi.org/10.1007/s11892-022-01442-6

9. Poudel, A., & Nissen, L. M. (2016). Telepharmacy: A pharmacist's perspective on the clinical benefits and challenges. **Integrated Pharmacy Research & Practice, 5**, 75–82.https://doi.org/10.2147/IPRP.S101685